Prosecutors say that patients at an Alaska-based clinic were underdosed, injected with free or expired drugs, and billed for ...
The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...
All 16 of the drug manufacturers that signed deals with Trump have issued price hikes this year, according to reports.
More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension ...
Lev Facher covers the U.S. addiction and overdose crisis. ROCHESTER, N.H. — Megan Merrill paused, mid-hike, as she surveyed the steep drop before her. She was standing on a five-foot snow drift, icy ...
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...
A new biosimilar, SYSA1902, shows comparable efficacy and safety to ustekinumab for treating moderate-to-severe plaque psoriasis, expanding patient options. A new biosimilar may offer a treatment ...
Celltrion's FDA approval of Steqeyma enhances pediatric psoriasis treatment, offering flexible dosing options for children with chronic inflammatory conditions. Celltrion announced the FDA had ...
In May 2025, the FDA approved numerous biosimilars as interchangeable with Stelara ® (ustekinumab) and Humira ® (adalimumab), bringing the total number of Stelara ® interchangeables to four, plus an ...
On May 5, 2025, Teva and Alvotech announced that the U.S. Food and Drug Administration (FDA) approved SELARSDI (ustekinumab-aekn) injection as an interchangeable biosimilar to the reference product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results